BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amir Mohammadamini. Comparison of the Extent of Self-Harm and Obsessive- Compulsive Disorder in Young Male Athletes and Non- Athletes DOI: 10.32474/CTGH.2022.03.000171 ISSN: 2641-1652 Amir Mohammadamini Published: Current Trends in Gastroenterology and Hepatology Published:In 2022. Lancet Gastroenterol Hepatol 2022:S2468-1253(21)00472-6. [PMID: 35180382 DOI: 10.1016/S2468-1253(21)00472-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 57.0] [Reference Citation Analysis]
Number Citing Articles
1 Wedemeyer H, Tergast TL, Lazarus JV, Razavi H, Bakoyannis K, Baptista-Leite R, Bartoli M, Bruggmann P, Buşoi CS, Buti M, Carballo M, Castera L, Colombo M, Coutinho RS, Dadon Y, Esmat G, Esteban R, Farran JC, Gillyon-Powell M, Goldberg D, Hutchinson S, Janssen HLA, Kalamitsis G, Kondili LA, Lambert JS, Marinho RT, Maticic M, Patricello A, Peck-Radosavljevic M, Pol S, Poljak M, Pop C, Sokol T, Sypsa V, Tözün N, Younossi Z, Aghemo A, Papatheodoridis GV, Hatzakis A. Securing wider EU commitment to the elimination of hepatitis C virus. Liver Int 2023;43:276-91. [PMID: 36196744 DOI: 10.1111/liv.15446] [Reference Citation Analysis]
2 Tergast TL, Protzer U, Zeuzem S, Heitmann L, Sarrazin C, Lehmann M, Ingiliz P, Cornberg M, Zimmermann R, Gerlich MG, Buggisch P, Wiebner B, Wedemeyer H. [Strategietreffen: Virushepatitis in Deutschland eliminieren]. Z Gastroenterol 2023;61:198-201. [PMID: 36736343 DOI: 10.1055/a-1978-9021] [Reference Citation Analysis]
3 Bittencourt PL, do Socorro Ferreira Iasi M, Viana MV, Crespo DM, Emerim E, de Almeida Borges PS, de Andrade ARC, Codes L, Ferraz MLG. Poor linkage to care may compromise the Brazilian plan for hepatitis C elimination. J Viral Hepat 2023;30:176-8. [PMID: 36302169 DOI: 10.1111/jvh.13762] [Reference Citation Analysis]
4 Rowan SE, Haukoos J, Kamis KF, Hopkins E, Gravitz S, Lyle C, Al-Tayyib AA, Gardner EM, Galbraith JW, Hsieh YH, Lyons MS, Rothman RE, White DAE, Morgan JR, Linas BP, Sabel AL, Wyles DL; DETECT Hep C Trials Investigators. The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis C. Trials 2023;24:63. [PMID: 36707909 DOI: 10.1186/s13063-022-07018-w] [Reference Citation Analysis]
5 Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, Su PY, Kao WY, Tsai MC, Tung HD, Cheng HT, Lee FJ, Huang CS, Huang KJ, Shih YL, Yang SS, Wu JH, Lai HC, Fang YJ, Chen PY, Hwang JJ, Tseng CW, Su WW, Chang CC, Lee PL, Chen JJ, Chang CY, Hsieh TY, Chang CH, Huang YJ, Kao JH. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatol Int 2023. [PMID: 36701081 DOI: 10.1007/s12072-022-10475-9] [Reference Citation Analysis]
6 Maalej NH, Collins IJ, Ades AE, Scott K, Judd A, Mostafa A, Chappell E, Hamdy-El-Sayed M, Gibb D, Pett S, Mariné-Barjoan E, Volokha A, Yazdanpanah Y, Deuffic-Burban S. Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine. J Hepatol 2023:S0168-8278(23)00014-4. [PMID: 36669704 DOI: 10.1016/j.jhep.2022.12.032] [Reference Citation Analysis]
7 Walters SM, Frank D, Felsher M, Jaiswal J, Fletcher S, Bennett AS, Friedman SR, Ouellet LJ, Ompad DC, Jenkins W, Pho MT. How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States. Int J Drug Policy 2023;112:103930. [PMID: 36641816 DOI: 10.1016/j.drugpo.2022.103930] [Reference Citation Analysis]
8 Vincent JP, Nyamasege C, Wang S, Madec Y, Shimakawa Y. Prevalence of hepatitis B, C, and D virus infection in Haiti: A systematic review and meta-analysis. Front Public Health 2022;10:1099571. [PMID: 36711383 DOI: 10.3389/fpubh.2022.1099571] [Reference Citation Analysis]
9 Robinson E, Byrne CJ, Carberry J, Radley A, Beer LJ, Inglis SK, Tait J, Macpherson I, Goldberg D, Hutchinson SJ, Hickman M, Dillon JF. Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts. BMC Public Health 2023;23:54. [PMID: 36611156 DOI: 10.1186/s12889-022-14911-1] [Reference Citation Analysis]
10 Musabaev E, Estes C, Sadirova S, Bakieva S, Brigida K, Dunn R, Kottilil S, Mathur P, Abutaleb A, Razavi-Shearer K, Anstiss T, Yusupaliev B, Razavi H. Viral hepatitis elimination challenges in low- and middle-income countries-Uzbekistan Hepatitis Elimination Program (UHEP). Liver Int 2023. [PMID: 36606729 DOI: 10.1111/liv.15514] [Reference Citation Analysis]
11 Spaderna M, Kattakuzhy S, Kang SJ, George N, Bijole P, Ebah E, Eyasu R, Ogbumbadiugha O, Silk R, Gannon C, Davis A, Cover A, Gayle B, Narayanan S, Pao M, Kottilil S, Rosenthal E. Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use. Int J Drug Policy 2023;111:103906. [PMID: 36384062 DOI: 10.1016/j.drugpo.2022.103906] [Reference Citation Analysis]
12 Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD, Fontaine G, Conway A, Bajis S, Valencia BM, Presseau J, Ward JW, Degenhardt L, Dore GJ, Hickman M, Vickerman P, Grebely J. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. Int J Drug Policy 2023;111:103917. [PMID: 36542883 DOI: 10.1016/j.drugpo.2022.103917] [Reference Citation Analysis]
13 Blach S, Brown KA, Brown RS, Gholam PM, Terrault NA, Estes C, Razavi HA. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress. J Infect Public Health 2023;16:64-70. [PMID: 36473359 DOI: 10.1016/j.jiph.2022.11.021] [Reference Citation Analysis]
14 van Santen DK, Sacks-Davis R, Stewart A, Boyd A, Young J, van der Valk M, Smit C, Rauch A, Braun DL, Jarrin I, Berenguer J, Lazarus JV, Lacombe K, Requena MB, Wittkop L, Leleux O, Salmon D, Bonnet F, Matthews G, Doyle JS, Spelman T, Klein MB, Prins M, Asselin J, Stoové MA, Hellard M; InCHEHC study group. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019. EClinicalMedicine 2023;56:101810. [PMID: 36618902 DOI: 10.1016/j.eclinm.2022.101810] [Reference Citation Analysis]
15 Cai D, Zhang D, Hu P, Ren H. A Comprehensive Hepatitis B Surface Antigen-Positive Patient-Centered Screening and Linkage to Care Strategies Targeting Microelimination of Hepatitis C Virus Infection in Chongqing, China. Can J Gastroenterol Hepatol 2022;2022:9644576. [PMID: 36606100 DOI: 10.1155/2022/9644576] [Reference Citation Analysis]
16 Mukherjee S, Kumar A, Samal J, Gupta E, Vivekanandan P, Menon MB. Selective Depletion of ZAP-Binding CpG Motifs in HCV Evolution. Pathogens 2022;12. [PMID: 36678391 DOI: 10.3390/pathogens12010043] [Reference Citation Analysis]
17 Ginès P, Buti M, Lazarus JV, Sangro B. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. Med Clin (Barc) 2022;159:598-603. [PMID: 36041936 DOI: 10.1016/j.medcli.2022.07.010] [Reference Citation Analysis]
18 Fukuoka T, Bessho K, Hosono S, Abukawa D, Mizuochi T, Ito K, Murakami J, Tanaka H, Miyoshi Y, Takano T, Tajiri H. The impact of treatment on the psychological burden of mothers of children with chronic hepatitis C virus infection: a multicenter, questionnaire survey. Sci Rep 2022;12:22116. [PMID: 36543833 DOI: 10.1038/s41598-022-25519-1] [Reference Citation Analysis]
19 Yousafzai MT, Alavi M, Valerio H, Hajarizadeh B, Grebely J, Dore GJ. Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study. J Viral Hepat 2022. [PMID: 36537024 DOI: 10.1111/jvh.13791] [Reference Citation Analysis]
20 Iversen J, Wand H, McManus H, Dore GJ, Maher L. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. Addiction 2022. [PMID: 36524842 DOI: 10.1111/add.16113] [Reference Citation Analysis]
21 Christensen PB, Debrabant B, Cowan S, Debrabant K, Øvrehus A, Duberg AS. Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020. Euro Surveill 2022;27. [PMID: 36695470 DOI: 10.2807/1560-7917.ES.2022.27.50.2200243] [Reference Citation Analysis]
22 Pimenov N, Kostyushev D, Komarova S, Fomicheva A, Urtikov A, Belaia O, Umbetova K, Darvina O, Tsapkova N, Chulanov V. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens 2022;11. [PMID: 36558817 DOI: 10.3390/pathogens11121482] [Reference Citation Analysis]
23 Zhang C, Lu J, Zhang Y, He P, Xia J, Huang M. Prevalence, diagnosis, treatment, and associated factors of hepatitis C in the United States from 1999 to 2018: A population-based cross-sectional study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.12.003] [Reference Citation Analysis]
24 Tan CK, Luo XS, Ong BS, Lin L, Ng KH. Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes. JGH Open 2023;7:48-54. [PMID: 36660045 DOI: 10.1002/jgh3.12850] [Reference Citation Analysis]
25 Malaguti A, Byrne CJ, Sani F, Power K, Eriksen A, Dillon JF. Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland. Behavioral Medicine 2022. [DOI: 10.1080/08964289.2022.2142501] [Reference Citation Analysis]
26 Nishikawa H, Asai A, Fukunishi S. The Significance of Zinc in Patients with Chronic Liver Disease. Nutrients 2022;14. [PMID: 36432541 DOI: 10.3390/nu14224855] [Reference Citation Analysis]
27 Dambadarjaa D, Radnaa O, Khuyag S, Shagdarsuren O, Enkhbayar U, Mukhtar Y, Tsogzolbaatar E, Nyam G, Shaarii S, Singh P, Takahashi M, Namdag B, Okamoto H. Hepatitis B, C, and D Virus Infection among Population Aged 10–64 Years in Mongolia: Baseline Survey Data of a Nationwide Cancer Cohort Study. Vaccines 2022;10:1928. [DOI: 10.3390/vaccines10111928] [Reference Citation Analysis]
28 Liu C, Peng C, Liu C, Chen C, Lo C, Tseng K, Su P, Kao W, Tsai M, Tung H, Cheng H, Lee F, Huang C, Huang K, Shih Y, Yang S, Wu J, Lai H, Fang Y, Chen P, Hwang J, Tseng C, Su W, Chang C, Lee P, Chen J, Chang C, Hsieh T, Chang C, Huang Y, Kao J. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.. [DOI: 10.21203/rs.3.rs-2215740/v1] [Reference Citation Analysis]
29 Guerra-Veloz MF, Han K, Oakes K, Robertson D, Mohamed A, Cannon M, Barnabas A, Shah S, Halford R, Dusheiko G, Agarwal K. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England. Am J Gastroenterol 2022. [PMID: 36191276 DOI: 10.14309/ajg.0000000000002041] [Reference Citation Analysis]
30 Burgui C, San Miguel R, Goñi-esarte S, Juanbeltz R, Úriz-otano JI, Reparaz J, Sarobe M, Zozaya JM, Castilla J. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal. Postgraduate Medicine 2022. [DOI: 10.1080/00325481.2022.2141499] [Reference Citation Analysis]
31 Ginès P, Buti M, Lazarus JV, Sangro B. Liver diseases: A sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. Medicina Clínica (English Edition) 2022. [DOI: 10.1016/j.medcle.2022.07.018] [Reference Citation Analysis]
32 Chadha N, Turner A, Sterling RK. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR. J Viral Hepat 2022. [PMID: 36301045 DOI: 10.1111/jvh.13763] [Reference Citation Analysis]
33 Darvishian M, Tang T, Wong S, Binka M, Yu A, Alvarez M, Alexander Velásquez García H, Adu PA, Jeong D, Bartlett S, Karamouzian M, Damascene Makuza J, Wong J, Ramji A, Woods R, Krajden M, Janjua N, Bhatti P. Chronic hepatitis C infection is associated with higher incidence of extrahepatic cancers in a Canadian population based cohort. Front Oncol 2022;12:983238. [DOI: 10.3389/fonc.2022.983238] [Reference Citation Analysis]
34 Spanoudaki A, Papadopoulos N, Trifylli EM, Koustas E, Vasileiadi S, Deutsch M. Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management. J Multidiscip Healthc 2022;15:2301-9. [PMID: 36247180 DOI: 10.2147/JMDH.S363177] [Reference Citation Analysis]
35 Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-samaniego J, Hernández-guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-frías F, Rodríguez M, Serra MÁ, Turnes J, Domínguez-hernández R, Casado MÁ, Calleja JL. Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analítica. Gastroenterología y Hepatología 2022. [DOI: 10.1016/j.gastrohep.2022.09.009] [Reference Citation Analysis]
36 Ramadan MS, Boccia F, Moretto SM, De Gregorio F, Gagliardi M, Iossa D, Durante-mangoni E, Zampino R. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. JCM 2022;11:5781. [DOI: 10.3390/jcm11195781] [Reference Citation Analysis]
37 Wang H, Chu F, Zhijie L, Bi Q, Lixin L, Zhuang Y, Xiaofeng Z, Niu X, Zhang D, Xi H, Li B. MTBP enhances the activation of transcription factor ETS-1 and promotes the proliferation of hepatocellular carcinoma cells. Front Oncol 2022;12:985082. [DOI: 10.3389/fonc.2022.985082] [Reference Citation Analysis]
38 Lothan R, Gutman N, Yamin D. Country versus pharmaceutical company interests for hepatitis C treatment. Health Care Manag Sci 2022. [PMID: 36001218 DOI: 10.1007/s10729-022-09607-2] [Reference Citation Analysis]
39 Hirata S, Havercamp K, Yamanashi Y, Udono T. Hepatitis C virus infection reduces the lifespan of chimpanzees used in biomedical research. Biol Lett 2022;18:20220048. [PMID: 35946233 DOI: 10.1098/rsbl.2022.0048] [Reference Citation Analysis]
40 Tai CM, Huang CK, Changchien TC, Lin PC, Wang DW, Chang TT, Chan HW, Chen TH, Tseng CH, Chen CC, Tsai CT, Sie YT, Yen YC, Yu ML. Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic. Viruses 2022;14:1637. [PMID: 35893702 DOI: 10.3390/v14081637] [Reference Citation Analysis]
41 Habas E, Farfar KL, Errayes N, Habas AM, Errayes M, Alfitori G, Rayani A, Elgara M, Al Adab AH, Elzouki A. Hepatitis Virus C-associated Nephropathy: A Review and Update. Cureus 2022. [DOI: 10.7759/cureus.27322] [Reference Citation Analysis]
42 Du R, Xu R, Huang J, Wang H, Wang M, Liao Q, Shan Z, Zhong H, Zheng Y, Rong X, Fu Y. HCV 6a was expanding and became the predominant subtype among blood donors between 2004 and 2019 in Guangdong, China. Virol Sin 2022:S1995-820X(22)00119-5. [PMID: 35842093 DOI: 10.1016/j.virs.2022.07.005] [Reference Citation Analysis]
43 Ferraz MLG, Piccoli LDZ, Rezende R, Borba LA, Junior AP, Cheinquer H, Silva GF, Ferreira PRA, Villela-nogueira CA, Mazo DF, Souza FF, Codes L, Ivantes CAP, Gomide GPM, Pereira GHS, Pessôa MG, França AVC, Pinto ADS, Teixeira R, Bittencourt PL. National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents. The Brazilian Journal of Infectious Diseases 2022;26:102388. [DOI: 10.1016/j.bjid.2022.102388] [Reference Citation Analysis]
44 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Terrault NA, Dufour JF, Schwabe RF, Wong VW. Breakthroughs in hepatology. J Hepatol 2022;76:1247-8. [PMID: 35589247 DOI: 10.1016/j.jhep.2022.04.001] [Reference Citation Analysis]
47 Ciupkeviciene E, Petkeviciene J, Sumskiene J, Dragunas G, Dabravalskis S, Kreivenaite E, Telksnys T, Urbonas G, Kupcinskas L. Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme. Viruses 2022;14:1192. [DOI: 10.3390/v14061192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Nevola R, Rosato V, Conturso V, Perillo P, Le Pera T, Del Vecchio F, Mastrocinque D, Pappalardo A, Imbriani S, Delle Femine A, Piacevole A, Claar E. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies. Biology 2022;11:805. [DOI: 10.3390/biology11060805] [Reference Citation Analysis]
49 Rosato V, Nevola R, Conturso V, Perillo P, Mastrocinque D, Pappalardo A, Le Pera T, Del Vecchio F, Claar E. Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic. Biology 2022;11:800. [DOI: 10.3390/biology11060800] [Reference Citation Analysis]
50 Rosato V, Kondili LA, Nevola R, Perillo P, Mastrocinque D, Aghemo A, Claar E. Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses 2022;14:1096. [DOI: 10.3390/v14051096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Karimi-Sari H, Rezaee-Zavareh MS. Altered hepatitis C testing and treatment beyond the COVID-19 pandemic. Public Health 2022:S0033-3506(22)00101-9. [PMID: 35568527 DOI: 10.1016/j.puhe.2022.03.018] [Reference Citation Analysis]
52 Madsen LW, Christensen PB, Hansen JF, Røge BT, Holm DK, Dröse S, Øvrehus A. Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial. Viruses 2022;14:614. [DOI: 10.3390/v14030614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 De A, Duseja A, Sood A. Who to Screen for Hepatitis C: That is the Question. J Clin Exp Hepatol 2022;12:1406-7. [PMID: 36340301 DOI: 10.1016/j.jceh.2022.10.004] [Reference Citation Analysis]
54 Santos APDT, Silva VCM, Mendes-corrêa MC, Lemos MF, Malta FDM, Santana RAF, Dastoli GTF, Castro VFDD, Pinho JRR, Moreira RC. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. Rev Inst Med trop S Paulo 2022;64:e61. [DOI: 10.1590/s1678-9946202264061] [Reference Citation Analysis]